Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Partnered Content
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Biosimilars Approvals Metabolic Disorders

Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation

  • News

Executive Summary

The Merck and Samsung Bioepis formulation of Sanofi's insulin glargine was tentatively approved by FDA, a designation that permits the drug to enter the market pending the resolution of ongoing patent litigation.

You may also be interested in...



UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.

FDA Makes It Official With Basaglar Approval For Diabetes

Eli Lilly/Boehringer Ingelheim’s insulin glargine product had already received tentative approval from FDA. The final approval clears the way for an eventual copycat version of Sanofi’s Lantus.

Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus

Eli Lilly’s copycat version of Sanofi’s blockbuster insulin Lantus could reach the market in the U.S. in December 2016 following a settlement agreement with Sanofi.

Table

View full table

Topics

Related Companies

Tags:
Biosimilars Approvals Metabolic Disorders
UsernamePublicRestriction

Register

GB001689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By